Market Cap
US$1.8b
Last Updated
2019/11/20 23:37 UTC
Data Sources
Company Financials +
Executive Summary
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases.
Snowflake
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Insmed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INSM has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
3.8%
INSM
3.2%
US Biotechs
0.5%
US Market
1 Year Return
18.6%
INSM
11.1%
US Biotechs
16.1%
US Market
Return vs Industry: INSM exceeded the US Biotechs industry which returned 11.1% over the past year.
Return vs Market: INSM exceeded the US Market which returned 16.1% over the past year.
Shareholder returns
| INSM | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.8% | 3.2% | 0.5% |
| 30 Day | 10.6% | 11.1% | 3.9% |
| 90 Day | 23.5% | 9.1% | 6.6% |
| 1 Year | 18.6%18.6% | 12.1%11.1% | 18.7%16.1% |
| 3 Year | 38.5%38.5% | 18.7%14.9% | 47.2%37.7% |
| 5 Year | 40.2%40.2% | 5.4%0.5% | 61.5%43.7% |
Price Volatility Vs. Market
How volatile is Insmed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Insmed Incorporated's (NASDAQ:INSM) Shift From Loss To Profit2 months ago | Simply Wall St
Insmed (NASDAQ:INSM) Shareholders Booked A 49% Gain In The Last Five Years2 months ago | Simply Wall St
Should You Take Comfort From Insider Transactions At Insmed Incorporated (NASDAQ:INSM)?Valuation
Is Insmed undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INSM ($20.18) is trading below our estimate of fair value ($53.17)
Significantly Below Fair Value: INSM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INSM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: INSM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INSM is overvalued based on its PB Ratio (5.9x) compared to the US Biotechs industry average (3x).
Next Steps
Future Growth
How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
71.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: INSM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: INSM's is expected to become profitable in the next 3 years.
Revenue vs Market: INSM's revenue (47.5% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: INSM's revenue (47.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSM is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Insmed performed over the past 5 years?
-28.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INSM has high quality earnings.
Growing Profit Margin: INSM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of -28.7% per year.
Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).
Return on Equity
High ROE: INSM has a negative Return on Equity (-96.34%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Insmed's financial position?
Financial Position Analysis
Short Term Liabilities: INSM's short term assets ($595.6M) exceeds its short term liabilities ($85.4M)
Long Term Liabilities: INSM's short term assets ($595.6M) exceeds its long term liabilities (373.7M)
Debt to Equity History and Analysis
Debt Level: INSM's debt to equity ratio (108.9%) is considered high.
Reducing Debt: INSM's debt to equity ratio has increased from 6.7% to 108.9% over the past 5 years.
Balance Sheet
Inventory Level: INSM has a low level of unsold assets or inventory.
Debt Coverage by Assets: INSM's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if INSM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Insmed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Insmed's salary, the management and board of directors tenure and is there insider trading?
6.3yrs
Average management tenure
CEO
Will Lewis (50yo)
7.2yrs
Tenure
US$5,943,159
Compensation
Mr. William H. Lewis, J.D., M.B.A., also known as Will, has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2 ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD5.94M) is above average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
6.3yrs
Average Tenure
51yo
Average Age
Experienced Management: INSM's management team is seasoned and experienced (6.3 years average tenure).
Board Age and Tenure
3.8yrs
Average Tenure
62yo
Average Age
Experienced Board: INSM's board of directors are considered experienced (3.8 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 122,316 |
| Max Price | US$3.40 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.
Management Team
Christine Pellizzari (51yo)
Chief Legal Officer & Corporate Secretary
- Tenure: 6.3yrs
- Compensation: US$2.03m
Will Lewis (50yo)
President
- Tenure: 7.2yrs
- Compensation: US$5.94m
Walter Perkins
Chief Technology Officer
- Tenure: 8.9yrs
Blaine Davis
Head of Investor Relations & Corporate Communications
- Tenure: 0yrs
S. Schaeffer (51yo)
Chief People Strategy Officer
- Tenure: 6.8yrs
- Compensation: US$1.56m
John Soriano (57yo)
Chief Compliance Officer
- Tenure: 1.8yrs
Roger Adsett (50yo)
Chief Operating Officer
- Tenure: 0yrs
- Compensation: US$2.67m
John Goll
Chief Accounting Officer
- Tenure: 0.7yrs
Drayton Wise
Senior VP & Head of United States
- Tenure: 0yrs
Paul Streck (55yo)
- Tenure: 0.8yrs
- Compensation: US$2.23m
Board Members
Steinar Engelsen (68yo)
Independent Director
- Tenure: 20yrs
- Compensation: US$225.00k
Davie McGirr (65yo)
Independent Director
- Tenure: 6.1yrs
- Compensation: US$225.00k
Mel Sharoky (68yo)
Independent Director
- Tenure: 18.5yrs
- Compensation: US$217.00k
Al Altomari (60yo)
Independent Director
- Tenure: 7.3yrs
- Compensation: US$230.00k
David Brennan (65yo)
Lead Independent Director
- Tenure: 1yrs
- Compensation: US$215.80k
Will Lewis (50yo)
President
- Tenure: 7.2yrs
- Compensation: US$5.94m
Clarissa Desjardins (52yo)
Director
- Tenure: 0yrs
Liz Anderson (62yo)
Independent Director
- Tenure: 1yrs
- Compensation: US$91.97k
Leo Lee (49yo)
Independent Director
- Tenure: 1.5yrs
- Compensation: US$190.17k
Company Information
Insmed Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Insmed Incorporated
- Ticker: INSM
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.803b
- Shares outstanding: 89.34m
- Website: https://www.insmed.com
Number of Employees
Location
- Insmed Incorporated
- Building 10
- 10 Finderne Avenue
- Bridgewater
- New Jersey
- 8807
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| INSM | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2000 |
| IM8N | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2000 |
| IM8N | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Jun 2000 |
| 0JAV | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 2000 |
| INSM * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 2000 |
Biography
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 23:37 |
| End of Day Share Price | 2019/11/20 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.